Sanaria's Vaccine Pipeline
Based on the innovative PfSPZ platform technology, Sanaria has a number of malaria vaccine candidates in various stages of R&D; and clinical evaluation.
IN THE LAB
PRE-CLINICAL
In vitro produced PfSPZ malaria vaccine
Genetically attenuated PfSPZ vaccines
Plasmodium vivax SPZ (for controlled human malaria infection and vaccination)
CLINICAL STUDIES
PHASE 1
SANARIA® PfSPZ-GA1 – genetically attenuated PfSPZ vaccine
PHASE 2
SANARIA® PfSPZ Vaccine – radiation attenuated PfSPZ vaccine
SANARIA® PfSPZ-CVac – infectious PfSPZ administered with malaria chemoprophylaxis